Multi-Spectroscopic, thermodynamic and molecular dynamic simulation studies for investigation of interaction of dapagliflozin with bovine serum albumin

被引:54
作者
Abdelaziz, Mohamed A. [1 ]
Shaldam, Moataz [2 ]
El-Domany, Ramadan A. [3 ]
Belal, Fathalla [4 ]
机构
[1] Kafrelsheikh Univ, Fac Pharm, Dept Pharmaceut Analyt Chem, POB 33516, Kafrelsheikh, Egypt
[2] Kafrelsheikh Univ, Fac Pharm, Dept Pharmaceut Chem, POB 33516, Kafrelsheikh, Egypt
[3] Kafrelsheikh Univ, Fac Pharm, Dept Microbiol & Immunol, POB 33516, Kafrelsheikh, Egypt
[4] Mansoura Univ, Fac Pharm, Dept Pharmaceut Analyt Chem, Mansoura 35516, Egypt
关键词
Dapagliflozin; Bovine serum albumin; Spectroscopy; Fluorescence; Quenching; Binding thermodynamic parameters; Docking; DRUG BINDING-SITES; PROTEIN INTERACTION; DOCKING; CHEMISTRY; ROLES;
D O I
10.1016/j.saa.2021.120298
中图分类号
O433 [光谱学];
学科分类号
0703 ; 070302 ;
摘要
Dapagliflozin (DAPA) is a selective sodium-glucose cotransporter-2 inhibitor that reduces renal glucose reabsorption. The drug has recently become a crucial milestone in the management of diabetes and heart failure. In this study, the interaction of DAPA with bovine serum albumin (BSA) was investigated for the first time using various fluorescence spectroscopic techniques, UV-absorption spectroscopy, molecular docking, and molecular dynamic (MD) simulation. The fluorescence spectroscopic titration study performed at different temperatures showed that DAPA quenched the fluorescence of BSA through a combination of dynamic and static mechanisms, which was confirmed by UV absorption, fluorescence-resonance energy transfer measurements, and MD simulation. The binding thermodynamic parameters demonstrated that the binding stoichiometry between BSA and DAPA was 1:1. Competitive binding experiments using site-specific markers as well as molecular docking studies showed that DAPA binds to site I on BSA. The positive values of enthalpy change (Delta H) and entropy change (Delta S) revealed that hydrophobic forces played a predominant role in the binding of DAPA to BSA, whereas the negative value of Gibbs free energy change (Delta G) indicated the spontaneity of the interaction. Moreover, the synchronous fluorescence spectroscopy has shown that DAPA binding to the protein molecule occurs in the vicinity of the tryptophan residue. These findings were confirmed by the molecular docking and MD simulation studies. (C) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页数:9
相关论文
共 51 条
[41]   Evaluation of dapagliflozin in the treatment of heart failure [J].
Sotirakos, Sara .
FUTURE CARDIOLOGY, 2020, 17 (03) :415-425
[42]  
SUDLOW G, 1976, MOL PHARMACOL, V12, P1052
[43]  
SUDLOW G, 1975, MOL PHARMACOL, V11, P824
[44]   Unravelling the interaction mechanism between clioquinol and bovine serum albumin by multi-spectroscopic and molecular docking approaches [J].
Tantimongcolwat, Tanawut ;
Prachayasittikul, Supaluk ;
Prachayasittikul, Virapong .
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 2019, 216 :25-34
[45]   Fluorescence spectral resolution of tryptophan residues in bovine and human serum albumins [J].
Tayeh, Nadim ;
Rungassamy, Tevamie ;
Albani, Jihad Rene .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2009, 50 (02) :107-116
[46]   Serum albumin: clinical significance of drug binding and development as drug delivery vehicle [J].
Tayyab, Saad ;
Feroz, Shevin Rizal .
ADVANCES IN PROTEIN CHEMISTRY AND STRUCTURAL BIOLOGY, VOL 123: TRANSPORT PROTEINS, 2021, 123 :193-218
[47]   The role of the protein-binding on the mode of drug action as well the interactions with other drugs [J].
Tesseromatis, Christine ;
Alevizou, Anastasia .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2008, 33 (04) :225-230
[48]  
Valeur B., 2012, MOL FLUORESCENCE PRI, DOI DOI 10.1002/9783527650002.CH10
[49]   SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients [J].
Vasquez-Rios, George ;
Nadkarni, Girish N. .
INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2020, 13 :281-296
[50]   The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial [J].
Wiviott, Stephen D. ;
Raz, Itamar ;
Bonaca, Marc P. ;
Mosenzon, Ofri ;
Kato, Eri T. ;
Cahn, Avivit ;
Silverman, Michael G. ;
Bansilal, Sameer ;
Bhatt, Deepak L. ;
Leiter, Lawrence A. ;
McGuire, Darren K. ;
Wilding, John P. H. ;
Gause-Nilsson, Ingrid A. M. ;
Langkilde, Anna Maria ;
Johansson, Peter A. ;
Sabatine, Marc S. .
AMERICAN HEART JOURNAL, 2018, 200 :83-89